2. Signaling Pathways
  3. Immunology/Inflammation
  4. PD-1/PD-L1

PD-1/PD-L1

PD-1/Programmed death-ligand 1

PD-1/PD-L1

Related Products

PDF 0.7 MB

Programmed death-1 (PD-1) is a cell surface receptor that functions as a T cell checkpoint and plays a central role in regulating T cell exhaustion. PD-1 is activated by the engagement of its ligands PDL-1 or PDL-2. PD-1 receptor delivers inhibitory checkpoint signals to activated T cells upon binding to its ligands PD-L1 and PD-L2 expressed on antigen-presenting cells and cancer cells, resulting in suppression of T-cell effector function and tumor immune evasion. Inhibiting the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway is an attractive strategy for tumor immunotherapy.

PD-1 is expressed on activated T cells, B cells, monocytes, dendritic cells (DCs), regulatory T cells (Tregs), and natural killer T cells (NKT). It is a member of a family of immunoglobulin domain (Ig) co-receptors that modify the outcome of activation of the T cell receptor by an antigen-presenting cell (APC) or infected target cell. PD-L1 is widely and constitutively expressed on both hematopoietic and nonhematopoietic cells; e.g., naive T and B cells, vascular endothelial cells, and pancreatic islet cells, whereas PD-L2 is exclusively and inducibly expressed on professional APCs.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P99709
    Lodapolimab
    		Inhibitor
    Lodapolimab (LY3300054) is an IgGλ anti-PD-1 monoclonal antibody.
    Lodapolimab
  • HY-163837
    PD-1/PD-L1-IN-48
    		Inhibitor
    PD-1/PD-L1-IN-48 (compound HD10) is a potent inhibitor of PD-1/PD-L1 interaction, with an IC50 of 3.1 nM. PD-1/PD-L1-IN-48 plays an important role in cancer research.
    PD-1/PD-L1-IN-48
  • HY-168080
    PD-1/PD-L1-IN-51
    		Inhibitor
    PD-1/PD-L1-IN-51 (Compound III-4) is a PD-1/PD-L1 inhibitor (IC50: 2.9 nM for hPD-L1). PD-1/PD-L1-IN-51 directly binds to PD-L1 to block the interaction between PD-1/PD-L1 and enhances IFN-γ release. PD-1/PD-L1-IN-51 has tumor inhibitory activity.
    PD-1/PD-L1-IN-51
  • HY-P10424
    OPBP-1
    		Inhibitor
    OPBP-1 is a D-peptide obtained by phage display screening, molecular docking and molecular dynamics simulation. OPBP-1 has high stability and strong antitumor and oral activity. OPBP-1 can selectively bind PD-L1 protein, significantly block the interaction between PD-1 and PD-L1, and this blocking effect helps to restore and improve the function of T lymphocytes and reduce the proportion of bone marrow derived suppressor cells (MDSCs) to combat tumor-induced immune escape. OPBP-1 can be used in cancer immunotherapy research.
    OPBP-1
  • HY-162356
    PD-L1-IN-4
    		Inhibitor
    PD-L1-IN-4 (Compound X18) is an orally active PD-L1 inhibitor that exhibits remarkable inhibitory activity against the PD-1/PD-L1 interaction (IC50 = 1.3 nM) and enhances PD-L1 inhibitory effect on T cells (EC50 = 152.8 nM). PD-L1-IN-4 can be used for the research of cancer.
    PD-L1-IN-4
  • HY-P990718
    Cemavafusp
    Cemavafusp is an anti-PD-L1 monoclonal antibody composed of a single chain variable fragment, an antibody heavy chain, and a kappa antibody light chain.
    Cemavafusp
  • HY-169392
    D5B
    		Inhibitor
    D5B is a potent and selective PD-L1 inhibitor. D5B has been modified by DBCO. The EC50 of D5B degrading PD-L1 in 4T1 and B16-F10 tumor cells are 5.4 μM and 6.2 μM, respectively. D5B can block PD-L1/PD-1 interaction and has anti-tumor activity.
    D5B
  • HY-P991078
    Anti-Mouse PD-1 (LALA-PG) Antibody (RMP1-14)
    		Inhibitor
    Anti-Mouse PD-1 (LALA-PG) Antibody (RMP1-14) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse PD-1.
    Anti-Mouse PD-1 (LALA-PG) Antibody (RMP1-14)
  • HY-163307
    PD-1/PD-L1-IN-39
    		Inhibitor
    PD-1/PD-L1-IN-39 (X 14) is an orally active PD-1/PD-L1 inhibitor with a IC50 value of 15.73 nM. PD-1/ PD-L1-in-39 has a good binding affinity for human and mouse PD-L1, with KD values of 14.62 nM and 392 nM, respectively. PD-1/PD-L1-IN-39 has antitumor activity.
    PD-1/PD-L1-IN-39
  • HY-146740
    PD-1/PD-L1-IN-27
    		Inhibitor
    PD-1/PD-L1-IN-27 is a potent PD-1/PD-L1 inhibitor with an IC50 value of 134 nM. PD-1/PD-L1-IN-27 shows antitumor effects with low T cell cytotoxicity. PD-1/PD-L1-IN-27 has the ability to activate CD8+ T cells and reduces T cell exhaustion.
    PD-1/PD-L1-IN-27
  • HY-159125
    PD-1/PD-L1-IN-47
    		Inhibitor
    PD-1/PD-L1-IN-47 (MolPort-001-742-690) is a PH-selective PD-1/PD-L1 signaling pathway inhibitor with significant affinity for PD-L1 under acidic conditions and lower toxicity. PD-1/PD-L1-IN-47 can be used in the study of tumors.
    PD-1/PD-L1-IN-47
  • HY-P99714
    Lorigerlimab
    		Inhibitor
    Lorigerlimab (MGD019) is a bispecific IgG4 dual-affinity re-targeting antibody (DART). Lorigerlimab can block PD-1 and CTLA-4, and improves T-cell responses. Lorigerlimab can be used for research of metastatic castration-resistant prostate cancer (mCRPC).
    Lorigerlimab
  • HY-159601
    CSN5-IN-1
    		Inhibitor
    CSN5-IN-1 (compound Ac-11) is an inhibitor of CSN5, with IC50 values of 12.56 μM and 19 μM as measured by FP assay and fluorescence assay, respectively. CSN5-IN-1 can also downregulate the expression of PD-L1 and upregulate the expression of NEDD8-Cul1 in cells.
    CSN5-IN-1
  • HY-145769
    N2S2-CBMBC
    N2S2-CBMBC, an N2S2 bromo-benzyl ether derivative, acts as a ligand and use 99mTc-labelled complexes 99mTc-N2S2-CBMBC can be used as an imaging agent to be applied to the aspect of detecting PD-L1 expression, realize the real-time, comprehensive and convenient detection of the PD-L1 level of tumors, and overcome the defects of an immunohistochemical method.
    N2S2-CBMBC
  • HY-P990171
    Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2)
    		Inhibitor
    Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse PD-L1/B7-H1.
    Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2)
  • HY-162399
    PD-L1-IN-6
    		Inhibitor
    PD-L1-IN-6 (Compound 16) is an orally active inhibitor for PD-L1 expression in neutrophil by targeting STAT3 with KD of 90.5 nmol/L. PD-L1-IN-6 promotes neutrophil-mediated antifungal immunoresponse.
    PD-L1-IN-6
  • HY-168078
    PD-1/PD-L1-IN-50
    		Inhibitor
    PD-1/PD-L1-IN-50 (Compound LG-12) is a PD-1/PD-L1 inhibitor. PD-1/PD-L1-IN-50 increases the secretion of IFN-γ to promote CD8 + T cell activation, and activates the antitumor immunity of T cells.
    PD-1/PD-L1-IN-50
  • HY-155681
    SWS1
    		Inhibitor
    SWS1 is a d-(+)-biotin-conjugated PD-L1 inhibitor (IC50: 1.8 nM) with anticancer activity. SWS1 can increase the number of tumor-infiltrating lymphocytes and exhibit anti-tumor efficacy in the B16-F10 mouse model (TGI=66.1%).
    SWS1
  • HY-172200
    PD-L1/HDAC6-IN-1
    		Inhibitor
    PD-L1/HDAC6-IN-1 (Compound HP29) is the inhibitor for PD-L1 and HDAC6 that inhibits the PD-L1/PD-1 interaction and HDAC6 with an IC50 of 26.8 nM and 69 nM. PD-L1/HDAC6-IN-1 enhances the killing ability of Jurkat T cells against HepG2 cells with an IC50 of 3.4 μM. PD-L1/HDAC6-IN-1 exhibits good pharmacokinetics characteristics in rats with a drug exposure of 871.62 ng·h/mL, and exhibits antitumor activity in mouse B16-F10 xenograft models.
    PD-L1/HDAC6-IN-1
  • HY-154869
    PD-1/PD-L1-IN-34
    		Inhibitor
    PD-1/PD-L1-IN-34 (Compound (1S,2S)-A25) inhibits PD-1/PD-L1 interaction (IC50=0.029 μM), with a selected binding affinity with PD-L1 (KD=0.1554 μM). PD-1/PD-L1-IN-34 inhibits tumor growth by activating the immune microenvironment.
    PD-1/PD-L1-IN-34
Cat. No. Product Name / Synonyms Application Reactivity